Adagene

Suzhou, China Founded: 2012 • Age: 14 yrs
Immunotherapy antibodies for cancer treatment are developed.
Request Access

About Adagene

Adagene is a company based in Suzhou (China) founded in 2012 by Peter Luo.. Adagene has raised $155 million across 5 funding rounds from investors including WuXi AppTec, General Atlantic and Sanofi. The company has 138 employees as of December 31, 2024. Adagene operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.

  • Headquarter Suzhou, China
  • Employees 138 as on 31 Dec, 2024
  • Founders Peter Luo
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Adagene, Inc. Sponsored Adr
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $103.2 K
    -99.43
    as on Dec 31, 2024
  • Net Profit
    $-33.42 M
    -76.41
    as on Dec 31, 2024
  • EBITDA
    $-35.03 M
    -34.69
    as on Dec 31, 2024
  • Total Equity Funding
    $155 M (USD)

    in 5 rounds

  • Latest Funding Round
    $25 M (USD), Post-IPO

    Jul 01, 2025

  • Investors
    WuXi AppTec

    & 12 more

  • Employee Count
    138

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Adagene

Adagene is a publicly listed company on the NASDAQ with ticker symbol ADAG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: ADAG . Sector: Health technology · USA
People of Adagene
Headcount 200-500
Employee Profiles 17
Board Members and Advisors 6
Employee Profiles
People
JC Xu
Chief Strategy Officer And Head Of Regulatory Affairs
People
Qinghai Zhao
Chief Manufacturing Officer
People
Guizhong Liu
Sr. Vp, Early Drug Discovery
People
Alexander Goergen
Head Of Business Development

Unlock access to complete

Board Members and Advisors
people
Zhu Li
Independent Director
people
Andy Cheung
Independent Director
people
Yumeng Wang
Director
people
Mervyn Turner
Director

Unlock access to complete

Funding Insights of Adagene

Adagene has successfully raised a total of $155M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Post-IPO — $25.0M
  • First Round

    (08 Dec 2014)

  • Investors Count 13
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2025 Amount Post-IPO - Adagene Valuation

investors

Jan, 2020 Amount Series D - Adagene Valuation General Atlantic
Mar, 2018 Amount Series C - Adagene Valuation Sequoia Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Adagene

Adagene has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include WuXi AppTec, General Atlantic and Sanofi. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity fund focused on global markets
Founded Year Domain Location
Venture capital investment and global platform support for startups.
Founded Year Domain Location
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Adagene

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Adagene

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Adagene Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Adagene

Adagene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Adagene

Frequently Asked Questions about Adagene

When was Adagene founded?

Adagene was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Where is Adagene located?

Adagene is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.

Who is the current CEO of Adagene?

Peter Luo is the current CEO of Adagene. They have also founded this company.

Is Adagene a funded company?

Adagene is a funded company, having raised a total of $155M across 5 funding rounds to date. The company's 1st funding round was a Series C of $50M, raised on Dec 08, 2014.

How many employees does Adagene have?

As of Dec 31, 2024, the latest employee count at Adagene is 138.

What is the annual revenue of Adagene?

Annual revenue of Adagene is $103.2K as on Dec 31, 2024.

What does Adagene do?

Adagene was founded in 2012 in Suzhou, China, and operates in the biotechnology sector focused on cancer immunotherapy. Antibodies are developed, including ADG106 as an agonist for CD137 in metastatic solid tumors, ADG126 targeting CTLA4 for cancer therapy, and ADG116 targeting a CTLA4 epitope in metastatic solid tumors and relapsedrefractory non-Hodgkins lymphoma. Operations center on advancing these therapies for oncology applications.

Who are the top competitors of Adagene?

Adagene's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

Is Adagene publicly traded?

Yes, Adagene is publicly traded on NASDAQ under the ticker symbol ADAG.

Who are Adagene's investors?

Adagene has 13 investors. Key investors include WuXi AppTec, General Atlantic, Sanofi, Fidelity International, and Eight Roads Ventures.

What is Adagene's ticker symbol?

The ticker symbol of Adagene is ADAG on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available